Effects of anagliptin on plasma glucagon levels and gastric emptying in patients with type 2 diabetes: An exploratory randomized controlled trial versus metformin

What Was Tested

Researchers studied Glucagon in this randomized controlled trial publication.

Glucagon has an important role in glucose homeostasis.

Recently, a new plasma glucagon assay based on liquid chromatography-high resolution mass spectrometry was developed.

The researchers evaluated the influence of a dipeptidyl peptidase-4 inhibitor (anagliptin) on plasma glucagon levels in Japanese patients with type 2 diabetes by using this new assay.

Who Took Part

The age groups tagged for this paper are young adults, adults, middle-aged adults and older adults, both men and women.

A liquid test meal labeled with sodium [13C] acetate was ingested before and after the treatment period.

How the Study Was Run

The researchers set it up as a randomized and open-label study.

The participants were allocated by chance, so the Glucagon group and the comparison group should start out alike.

Everyone knew when Glucagon was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Samples of blood and expired air were collected over 3 h.

Plasma levels of glucose, glucagon, C-peptide, glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) were measured, and gastric emptying was also evaluated.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Gastric Emptying, Glucagon, Hypoglycemic Agents, Mass Spectrometry, Metformin and Pyrimidines.

Author keywords: DPP-4 inhibitor and Type 2 diabetes.

What This Means in Plain Language

The paper is a randomized and open-label study of Glucagon.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (Diabetes research and clinical practice), a journal based in Ireland.

More context: the Glucagon compound page, all human trials.